Detail akcie Addex Pharmaceut online

Business Summary: Addex Therapeutics Ltd is a Switzerland-based clinical-stage pharmaceutical company. The Company focuses on development and commercialization of orally available small molecule drugs known as allosteric modulators for neurological disorders. The Company’s clinical programs pipeline include dipraglurant (mGlu5 NAM), which is Phase 2a placebo-controlled clinical trial for Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID, and ADX71149 (mGlu2 positive allosteric modulator or PAM), which is being developed in collaboration by its partner Janssen Pharmaceuticals, Inc to treat schizophrenia and anxious depression. It also is advancing several preclinical programs, including GABABPAM for pain, overactive bladder and other disorders, mGlu7 NAM for post-traumatic stress disorder, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Addex Therapeutics Ltd revenues increased 14% to SF1.6M. Net loss decreased 49% to SF10.6M. Revenues reflect Revenue from contract with customer increase of 13% to SF1.6M, Other income increase of 51% to SF34K. Lower net loss reflects Stock-based Compensation in SGA decrease of 54% to SF1.2M (expense), Stock-based Compensation in R&D decrease of 46% to SF571K (expense).